Cosmax partners with two major Chinese cosmetic brands South Korean ODM forms JV with Florasis and Yatsen
Translated by Kim So-in 공개 2021-09-09 08:11:05
이 기사는 2021년 09월 09일 08:08 thebell 에 표출된 기사입니다.
South Korean original development manufacturer (ODM) Cosmax has formed a strategic alliance with China’s top two online cosmetic brands, Florasis and Yatsen.Cosmax’s Chinese subsidiary Cosmax China has established a joint venture (JV) specialized in R&D, in partnership with Florasis last month, industry sources said on Wednesday. The JV is 60% owned by Florasis and 40% owned by Cosmax China.
The JV has been formed one year after Cosmax Guangzhou created Yatsen Biotechnology, a 51:49 joint venture it formed with Yatsen, which owns Perfect Diary, in 2020.
Cosmax seemingly aims to secure Florasis as its client through the latest alliance. Florasis overtook Perfect Diary as the top online cosmetic brand last year. Revenue of Florasis increased 200% to 3 billion yuan ($464.4 million) in 2021 from 1.01 billion yuan in 2019. Perfect Diary’s revenue increased from 3.5 billion yuan to 5.2 billion yuan during the same period.
Florasis is expected to cement its position this year. The company recorded revenue of 850 million yuan through Alibaba in the first quarter of this year while Perfect Diary recorded 690 million yuan. Florasis plans to create a JV with Unilever to launch a high-end cosmetic brand.
In response to the trend, Cosmax has formed a solid relationship with the two Chinese firms by forming a JV with Perfect Diary through Cosmax Guangzhou last year and creating another JV with Florasis through Cosmax China in August of this year.
Cosmax has Cosmax East as its holding company in China and has two production units, Cosmax Guangzhou and Cosmax China. The two production units have a combined production capacity of 720 million units, the largest among all cosmetic manufacturers in China. Based on the new partnerships, Cosmax plans to manufacture around 500 million cosmetic products in China this year.
“Nothing has been finalized regarding a joint venture with Florasis,” said an official at Cosmax.
Yatsen Biotechnology received 16 billion won ($13.7 million) from its two parent companies through two rounds of rights offering this year. The proceeds are expected to be used to construct a production plant, which is likely to be completed around 2023. (Reporting by Hyo-jeom Jun)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”